http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 29 Jun 2026 16:33:43 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/Jones+Trading+Starts+Alterity+Therapeutics+%28ATHE%29+at+Buy/26706907.html (Updated - June 29, 2026 4:33 PM EDT) <p>Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ: ATHE) with a Buy rating and a price target of $16.00.</p><p>The analyst comments "ATH434 is a potential best-in-disease therapy. ATH434 targets excess labile iron, reducing oxidative stress-driven α-synuclein aggregation in the brain, the main driver of MSA pathology. In Ph2, ATH434 nearly halved the rate of MSA progression as assessed by mUMSARS I, delivering one of the most compelling treatment effects in the space (compare on Pg 15). ■ KOL feedback supports ATH434 potential. With all prior MSA candidates having met failures, http://www.streetinsider.com/New+Coverage/Jones+Trading+Starts+Alterity+Therapeutics+%28ATHE%29+at+Buy/26706907.html Mon, 29 Jun 2026 16:33:43 -0400 ATHE http://www.streetinsider.com/Analyst+Comments/Jones+Trading+Starts+Alterity+Therapeutics+%28ATHE%29+at+Buy/26706907.html (Updated - June 29, 2026 4:33 PM EDT) <p>Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ: ATHE) with a Buy rating and a price target of $16.00.</p><p>The analyst comments "ATH434 is a potential best-in-disease therapy. ATH434 targets excess labile iron, reducing oxidative stress-driven α-synuclein aggregation in the brain, the main driver of MSA pathology. In Ph2, ATH434 nearly halved the rate of MSA progression as assessed by mUMSARS I, delivering one of the most compelling treatment effects in the space (compare on Pg 15). ■ KOL feedback supports ATH434 potential. With all prior MSA candidates having met failures, http://www.streetinsider.com/Analyst+Comments/Jones+Trading+Starts+Alterity+Therapeutics+%28ATHE%29+at+Buy/26706907.html Mon, 29 Jun 2026 16:33:43 -0400 ATHE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+15++Filed+by%3A+Babarczy+Julian+Michael/26681028.html si-local-file:///var/storage/secattach/20260623/26681028.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+15++Filed+by%3A+Babarczy+Julian+Michael/26681028.html Tue, 23 Jun 2026 19:58:00 -0400 ATHDA ATHE O.00730626 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+15++Filed+by%3A+Babarczy+Julian+Michael/26681028.html si-local-file:///var/storage/secattach/20260623/26681028.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+15++Filed+by%3A+Babarczy+Julian+Michael/26681028.html Tue, 23 Jun 2026 19:58:00 -0400 ATHDA ATHE O.00730626 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+15++Filed+by%3A+Babarczy+Julian+Michael/26681028.html si-local-file:///var/storage/secattach/20260623/26681028.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+15++Filed+by%3A+Babarczy+Julian+Michael/26681028.html Tue, 23 Jun 2026 19:58:00 -0400 ATHDA ATHE O.00730626 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+15++Filed+by%3A+Gozlan+Lawrence+Bernard/26680997.html si-local-file:///var/storage/secattach/20260623/26680997.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+15++Filed+by%3A+Gozlan+Lawrence+Bernard/26680997.html Tue, 23 Jun 2026 19:38:00 -0400 ATHDA ATHE O.00730626 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+15++Filed+by%3A+Gozlan+Lawrence+Bernard/26680997.html si-local-file:///var/storage/secattach/20260623/26680997.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+15++Filed+by%3A+Gozlan+Lawrence+Bernard/26680997.html Tue, 23 Jun 2026 19:38:00 -0400 ATHDA ATHE O.00730626 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+15++Filed+by%3A+Gozlan+Lawrence+Bernard/26680997.html si-local-file:///var/storage/secattach/20260623/26680997.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+15++Filed+by%3A+Gozlan+Lawrence+Bernard/26680997.html Tue, 23 Jun 2026 19:38:00 -0400 ATHDA ATHE O.00730626 http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Assumes+Alterity+Therapeutics+%28ATHE%29+at+Buy/26650822.html <p>Ladenburg Thalmann assumes coverage on Alterity Therapeutics (NASDAQ: ATHE) with a Buy rating.</p><p>For an analyst ratings summary and ratings history on Alterity Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=ATHE">click here</a>. For more ratings news on Alterity Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=ATHE&amp;type=analyst">click here</a>.</p><p>Shares of Alterity Therapeutics closed at $4.41 yesterday.</p> http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Assumes+Alterity+Therapeutics+%28ATHE%29+at+Buy/26650822.html Tue, 16 Jun 2026 08:04:50 -0400 ATHE http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+30/26594902.html si-local-file:///var/storage/secattach/20260603/26594902.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+30/26594902.html Wed, 03 Jun 2026 06:05:00 -0400 ATHE O.00730626 PBN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+30/26594902.html si-local-file:///var/storage/secattach/20260603/26594902.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+30/26594902.html Wed, 03 Jun 2026 06:05:00 -0400 ATHE O.00730626 PBN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+30/26594902.html si-local-file:///var/storage/secattach/20260603/26594902.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+Jun+30/26594902.html Wed, 03 Jun 2026 06:05:00 -0400 ATHE O.00730626 PBN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+May+31/26570414.html si-local-file:///var/storage/secattach/20260529/26570414.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+May+31/26570414.html Fri, 29 May 2026 06:07:00 -0400 ATHE O.00730626 PBN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+May+31/26570414.html si-local-file:///var/storage/secattach/20260529/26570414.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+May+31/26570414.html Fri, 29 May 2026 06:07:00 -0400 ATHE O.00730626 PBN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+May+31/26570414.html si-local-file:///var/storage/secattach/20260529/26570414.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ALTERITY+THERAPEUTICS+++++For%3A+May+31/26570414.html Fri, 29 May 2026 06:07:00 -0400 ATHE O.00730626 PBN http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133 http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html <p>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.</p> <p>The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.</p> <p>Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html Tue, 19 May 2026 07:25:17 -0400 A.06822034 A.19718279 A.31293549 A.50216778 A.60012004 ATH ATH.AX ATHE O.00573636 O.00730626 O.01304637 O.01951358 O.20026344 O.21962133